Skip to main content

Advertisement

Table 5 Resource use by predictive biomarker testing status in Japan, Korea, Taiwan, and Brazil

From: Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study

  Japan
(N = 175)
Korea
(N = 150)
Taiwan
(N = 217)
Brazil
(N = 175)
EGFR/ALK tested Not tested EGFR/ALK tested Not tested EGFR/ALK tested Not tested EGFR/ALK tested Not tested
Pos Neg/Unk Pos Neg/Unk Pos Neg/Unk Pos Neg/Unk
First-line therapy N = 49 N = 81 N = 45 N = 53 N = 59 N = 38 N = 126 N = 59 N = 32 N = 13 N = 61 N = 101
No. inpatient staysa 44 129 69 89 82 80 90 83 27 5 17 20
 Hospital 44 (100) 129 (100) 69 (100) 89 (100) 82 (100) 80 (100) 90 (100) 83 (100) 27 (100) 5 (100) 17 (100) 20 (100)
No. hospitalizationsb 44 131 69 89 82 80 90 83 29 5 19 20
 Normal ward 44 (100) 129 (99) 69 (100) 89 (100) 82 (100) 80 (100) 90 (100) 83 (100) 27 (93) 4 (80) 17 (90) 20 (100)
 ICU 0 2 (2) 0 0 0 0 0 0 2 (7) 1 (20) 2 (11) 0
No. hospitalizations with LOSc 43 125 68 89 82 78 89 83 27 5 16 20
 Mean (SD) days 25.3 (16.9) 18.9 (15.4) 15.5 (12.8) 6.7 (7.4) 7.7 (11.1) 6.8 (9.9) 12.9 (14.7) 4.7 (3.3) 8.6 (8.6) 30.8 (24.2) 17.8 (25.7) 12.9 (14.8)
 Median (range) 21 (2–69) 13 (1–81) 13 (2–62) 3 (1–39) 3 (1–47) 3 (1–45) 7 (1–71) 3 (1–17) 5 (2–31) 22 (4–68) 6 (1–77) 6 (2–55)
Outpatient visits, nd 34 58 33 75 80 41 81 44 24 8 41 49
 Mean (SD) visits 17.5 (13.0) 14.9 (23.7) 16.5 (18.4) 11.8 (11.0) 14.2 (14.5) 11.3 (6.9) 16.3 (17.1) 8.0 (7.0) 17.0 (17.4) 8.3 (7.5) 9.5 (7.7) 5.1 (5.9)
 Median (range) 15 (1–51) 7 (1–124) 8 (1–62) 9 (1–51) 9 (1–58) 11 (1–27) 12 (1–109) 6 (1–27) 12 (2–76) 6 (2–22) 8 (1–35) 4 (1–36)
No. outpatient visits 595 863 546 882 1132 465 1321 352 407 66 389 251
Second-line therapy N = 32 N = 46 N = 27 N = 37 N = 37 N = 22 N = 85 N = 44 N = 26 N = 8 N = 42 N = 41
No. inpatient staysa 26 27 24 29 18 32 120 28 13 1 11 10
 Hospital 26 (100) 27 (100) 24 (100) 29 (100) 18 (100) 31 (97) 120 (100) 28 (100) 13 (100) 1 (100) 11 (100) 10 (100)
 Hospice 0 0 0 0 0 1 (3) 0 0 0 0 0 0
No. hospitalizationsb 26 27 24 29 18 33 120 28 13 1 11 10
 Normal ward 26 (100) 27 (100) 24 (100) 29 (100) 17 (94) 31 (94) 120 (100) 28 (100) 13 (100) 1 (100) 11 (100) 10 (100)
 ICU 0 0 0 0 1 (6) 2 (6) 0 0 0 0 0 0
No. hospitalizations with LOSc 26 27 23 29 18 31 120 28 13 1 11 10
 Mean (SD) days 21.7 (15.0) 21.5 (16.2) 22.0 (16.4) 8.7 (11.5) 8.2 (7.1) 5.9 (5.4) 6.3 (7.4) 12.5 (15.7) 12.2 (10.5) 5.0 (n/a) 6.7 (5.3) 11.8 (8.8)
 Median (range) 17 (3–63) 17 (3–74) 15 (4–54) 4 (1–56) 8 (1–26) 2 (1–18) 3 (1–52) 6 (3–69) 9 (3–37) 5 6 (2–21) 9 (2–30)
Outpatient visits, nd 18 26 19 48 41 18 45 27 18 2 22 18
 Mean (SD) visits 6.8 (7.8) 7.9 (6.6) 16.1 (13.8) 14.8 (14.0) 8.6 (7.2) 9.6 (13.2) 11.7 (11.4) 19.9 (23.6) 17.8 (19.7) 3.0 (0) 5.7 (4.9) 2.9 (2.0)
 Median (range) 3 (1–24) 6 (1–26) 14 (2–49) 8 (1–49) 5 (1–21) 5 (1–45) 9 (1–55) 12 (1–92) 12 (1–68) 3 (3–3) 5 (1–18) 3 (1–6)
No. outpatient visits 122 205 305 710 351 172 525 537 320 6 126 53
  1. aTotal number of inpatient stays, defined as one or more nights in a hospital or hospice. There were no hospice stays in Japan, Korea, Taiwan, or Brazil in association with first-line therapy
  2. bTotal number of hospitalizations, not including hospice stays
  3. cTotal number of hospitalizations with non-missing data regarding length of stay (LOS)
  4. dNumber of patients who had ≥1 outpatient visits
  5. ALK anaplastic lymphoma kinase, EGFR epidermal growth factor receptor, LOS length of stay, Neg/Unk negative/unknown, No. number of, OP outpatient, Pos positive